The point is that most customers in the Third World are not able to afford the price point that makes such medicines profitable.
The workaround since 2000-01 or so has been differential pricing or licensing for the Third World. But this took decades to get agreements for that to happen.
Comments
The point is that most customers in the Third World are not able to afford the price point that makes such medicines profitable.
The workaround since 2000-01 or so has been differential pricing or licensing for the Third World. But this took decades to get agreements for that to happen.
Here's a good page about the situation with HIV drugs. http://www.avert.org/generic.htm